These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 21241236)
1. Treatment options for cystic fibrosis: state of the art and future perspectives. Sears EH; Gartman EJ; Casserly BP Rev Recent Clin Trials; 2011 May; 6(2):94-107. PubMed ID: 21241236 [TBL] [Abstract][Full Text] [Related]
2. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Proesmans M; Vermeulen F; De Boeck K Eur J Pediatr; 2008 Aug; 167(8):839-49. PubMed ID: 18389279 [TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for cystic fibrosis: what's in the pipeline? Frerichs C; Smyth A Expert Opin Pharmacother; 2009 May; 10(7):1191-202. PubMed ID: 19405793 [TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators. Perrem L; Ratjen F Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088 [TBL] [Abstract][Full Text] [Related]
5. Macromolecular interactions and ion transport in cystic fibrosis. Guggino WB; Banks-Schlegel SP Am J Respir Crit Care Med; 2004 Oct; 170(7):815-20. PubMed ID: 15447951 [TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Rogan MP; Stoltz DA; Hornick DB Chest; 2011 Jun; 139(6):1480-1490. PubMed ID: 21652558 [TBL] [Abstract][Full Text] [Related]
8. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. Boucher RC; Knowles MR; Johnson LG; Olsen JC; Pickles R; Wilson JM; Engelhardt J; Yang Y; Grossman M Hum Gene Ther; 1994 May; 5(5):615-39. PubMed ID: 7519885 [TBL] [Abstract][Full Text] [Related]
9. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Kunzelmann K; Mall M Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996 [TBL] [Abstract][Full Text] [Related]
11. New treatments targeting the basic defects in cystic fibrosis. Fajac I; Wainwright CE Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723 [TBL] [Abstract][Full Text] [Related]
12. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
13. [Physiopathology of cystic fibrosis lung disease]. Chinet T Rev Mal Respir; 1999 Jun; 16(3):339-45. PubMed ID: 10472642 [TBL] [Abstract][Full Text] [Related]
14. Structure and function of the cystic fibrosis transmembrane conductance regulator. Morales MM; Capella MA; Lopes AG Braz J Med Biol Res; 1999 Aug; 32(8):1021-8. PubMed ID: 10454765 [TBL] [Abstract][Full Text] [Related]
15. New and emerging therapies for pulmonary complications of cystic fibrosis. Tonelli MR; Aitken ML Drugs; 2001; 61(10):1379-85. PubMed ID: 11558827 [TBL] [Abstract][Full Text] [Related]
16. Two cystic fibrosis transmembrane conductance regulator mutations have different effects on both pulmonary phenotype and regulation of outwardly rectified chloride currents. Fulmer SB; Schwiebert EM; Morales MM; Guggino WB; Cutting GR Proc Natl Acad Sci U S A; 1995 Jul; 92(15):6832-6. PubMed ID: 7542778 [TBL] [Abstract][Full Text] [Related]